Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chaperonin containing TCP1 subunit 7 pseudogene 2 (CCT7P2) is classified as a pseudogene derived from the functional gene CCT7, which encodes a subunit of the chaperonin containing TCP1 complex (TRiC/CCT)[1][4]. As a pseudogene, CCT7P2 is not known to produce a functional protein, and there is no evidence supporting its role as a therapeutic target, receptor, enzyme, transporter, or any other type of druggable entity[1][4]. Its main designation in scientific databases is as a non-coding, inactive gene segment related to the active CCT7 gene, which is involved in protein folding and cellular chaperone processes[1][4]. There is no documentation linking CCT7P2 specifically to diseases, drug interactions, or use as a biomarker. Additional notes: - The functional, protein-coding counterpart, CCT7, is involved in protein folding (via the TRiC complex) and associated with various cell processes, and diseases, but CCT7P2 itself—being a pseudogene—does not have such roles[5][6][7]. - Because it is a pseudogene, there is no established therapeutic mechanism or safety profile, and it is not a focus of drug targeting in current biomedical research[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chaperonin containing TCP1 subunit 7 pseudogene 2 (CCT7P2).